Price: quote on request. Your total cost is quoted in writing per case.
We reply within one business day
Get my quote

Primary sclerosing cholangitis (PSC): what families in the Gulf should know about treatment access

A plain guide for families in the Gulf, checked against US FDA labels, Gulf drug registers and published medical research.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Primary sclerosing cholangitis: the short answer

As of 17 October 2026, we found no medicine approved by the US FDA specifically for primary sclerosing cholangitis. Care focuses on symptoms and on support from specialists. Families can ask their doctor about clinical trials. Reserve Meds is a digital health company and can explain how access routes work. We do not diagnose or prescribe.

  • US FDA-approved medicines for this condition: none found on 17 October 2026.
  • Options to discuss with your specialist: symptom treatment, clinical trials, expanded access.
  • Price: Quote on request for any prescribed medicine.

What is primary sclerosing cholangitis?

Primary sclerosing cholangitis (PSC) affects the bile ducts that carry bile from the liver. Inflammation causes scarring and narrowing of the ducts, so bile builds up in the liver and damages it over time, which can lead to cirrhosis and liver failure.[1]

PSC is usually diagnosed around age 40 and affects men about twice as often as women. Many people have no symptoms at diagnosis, and liver problems are found on routine blood tests. Early symptoms can include tiredness, abdominal discomfort and severe itching, later followed by jaundice and an enlarged spleen.[1]

PSC is often linked with inflammatory bowel disease, especially ulcerative colitis, although the reason is unclear. Care is led by liver specialists. A Saudi study followed outcomes such as liver decompensation, bile duct and liver cancers and liver transplantation.[1, 2]

Primary sclerosing cholangitis in the Gulf

A Saudi referral center reviewed 87 patients with large duct PSC diagnosed from 2009 to 2020. 59.8% also had inflammatory bowel disease, and patients without it had more hepatic decompensation. Overall mortality was 12.8%.[2]

Treatment options and access from the Gulf

No US-approved medicine yet. We searched the US label database (DailyMed) on 17 October 2026 and found no medicine approved specifically for primary sclerosing cholangitis.[3] Your specialist may still prescribe approved medicines for symptoms or complications. If one of them is not available in your country, the same legal import route described below applies.

Clinical trials and expanded access. New treatments are tested in clinical trials, which you can search with your doctor on ClinicalTrials.gov. A medicine that is still investigational can only be used inside a trial or through a manufacturer's expanded-access (compassionate use) program, which the treating physician must request. We can explain how this works, but we do not supply investigational medicines.[4, 5]

If a prescribed medicine is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.[6, 7] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.

Who does what

  • Your treating specialist decides whether a medicine is right for the patient and writes the letter.
  • The hospital checks local supply, files any import request, and gives the treatment safely.
  • The national regulator decides whether to approve the import of a medicine that is not registered.
  • The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
  • Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

  • A letter from the treating specialist with the diagnosis, past treatments and why the medicine is being considered
  • Reports that confirm the diagnosis, such as laboratory, genetic, imaging or pathology results, translated into English where needed
  • Recent clinic notes and a list of current medicines
  • For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
  • Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for primary sclerosing cholangitis

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Include the country code, for example +966 or +971.
Message us on WhatsApp

No account needed. We reply within one business day. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

Frequently asked questions

Is there an FDA-approved medicine for primary sclerosing cholangitis?

Not that we found. On 17 October 2026 we found no medicine in the US label database approved specifically for primary sclerosing cholangitis. This can change, so ask your specialist about the latest options.

Can Reserve Meds get an investigational medicine?

No. Investigational medicines are only available inside clinical trials or through a manufacturer's expanded-access program requested by the treating physician. We can explain the route, but we do not supply them.

How much does access cost?

Quote on request. Any medicine your specialist prescribes is quoted in writing for your case before you commit, including shipping, import steps and coordination. No hidden charges.

Does Reserve Meds diagnose or prescribe?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.

Is PSC linked with bowel disease?

Yes. MedlinePlus Genetics notes that PSC is often associated with inflammatory bowel disease, and in the Saudi cohort 59.8% of patients had both.

Are there clinical trials for PSC?

Research is ongoing. You can search ClinicalTrials.gov with your hepatologist. Investigational medicines are only available inside trials or through a manufacturer's expanded-access program requested by the treating physician.

Sources for the last two answers: [1, 2] [4, 5]

Sources

Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.

  1. MedlinePlus Genetics (US National Library of Medicine): Primary sclerosing cholangitis
  2. AlGhamdi et al. Large duct primary sclerosing cholangitis with or without inflammatory bowel disease in Saudi patients. Saudi J Gastroenterol 2025 (PubMed 41051259)
  3. DailyMed (US National Library of Medicine): US drug label database, searched 17 October 2026
  4. ClinicalTrials.gov (US National Library of Medicine): search for clinical studies
  5. US FDA: Expanded Access (compassionate use), information for patients and physicians
  6. SFDA: Special Access Program (SAP) guidance, version 1.0
  7. NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products

Related

This page is general health information, not medical advice. It does not replace a consultation with your doctor.

WhatsApp